Using Sirolimus to Prevent Functional Decline in Older Adults
Official title: Sirolimus in Older Adults- Randomized Trial Assessing the Improvement in Phenotypic/Functional Biomarkers of Aging
Run by University of Texas Southwestern Medical Center · NCT05237687 · Data updated 2026-11-12
This study is testing if the drug sirolimus can help older adults aged 65 to 80 stay healthier and maintain their daily activities as they age.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 65 Years to 80 Years |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | University of Texas Southwestern Medical Center Academic / other |
| Locations | 1 site (Dallas, Texas) |
| Status | Recruiting |
| Started | March 31, 2026 |
| Main results expected | November 2027 |
| Study ends | January 2028 |
| Registry record updated | June 25, 2026 |
| Trial ID | NCT05237687 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 65 to 80 who are competent to provide informed consent and meet specific health criteria.
✕Probably not a fit
Patients with severe renal impairment, chronic liver disease, or significant cardiovascular issues may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the use of sirolimus, an immunosuppressive drug, to prevent functional decline associated with aging in adults aged 65 to 80. The study aims to explore how sirolimus affects the mTOR signaling pathway, which is linked to various age-related diseases and conditions. By targeting this pathway, the trial seeks to identify a new therapeutic intervention that could mitigate the degenerative processes of aging. Participants will be closely monitored for changes in their functional abilities and overall health.
Why it matters
Potential benefit: If successful, this intervention could significantly improve the quality of life for older adults by slowing down the aging process and reducing the risk of chronic diseases.
How similar studies have gone: While the use of sirolimus in aging is a novel approach, previous studies have shown promise in targeting the mTOR pathway for various diseases, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients should be adults 65-80 years * Women who are postmenopausal\* or status post-surgical sterilization only * Competent to provide Informed Consent Exclusion Criteria: * Creatinine clearance \<30 mL/min * Underlying chronic liver disease * Other investigational therapy received within 1 month prior to screening visit * Pulmonary Arterial Hypertension (PAH), mean Pulmonary Arterial Presure(mPAP)\>30 mm Hg * Extrapulmonary physiological restriction (e.g. chest wall abnormality, large pleural effusion) * Cardiovascular diseases, any of the following: Myocardial infarction within 6 months, planned coronary artery disease intervention , left ventricular EF \<45% * History of haemorrhagic central nervous system (CNS) event within 1 year from screening visit. * Any of the following within 3 months of screening visit :Haemoptysis or haematuria;Active gastro-intestinal (GI) bleeding or GI - ulcers; Major injury or surgery * History of thrombotic event (including, DVT, PE, stroke and transient ischemic attack) within 1 year from screening visit. * Other disease that may interfere with testing procedures or in the judgment of the Investigator may interfere with trial participation or may put the patient at risk when participating in this trial. * Planned major surgical procedures. * Women who are pregnant, nursing, or who plan to become pregnant while in the trial. * Concurrent active alcohol or drug abuse. * Clinically significant cognitive impairment * Functional impairment (defined by ADL status) * Patients not able to understand or follow trial procedures
Where it's running
-
UT Southwestern Medical Center
Dallas, Texas, United States Recruiting
Study contacts
- Principal investigator: Irina Timofte, M.D. — University of Texas Southwestern Medical Center
- Study coordinator: Irina Timofte
- Email: Irina.Timofte@utsouthwestern.edu
- Phone: 2163347534
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Aquatic power training dosing strategies and creatine in older adults
This trial tests whether different aquatic power training dosing methods and creatine supplementation help improve function in community-dwelling adults aged 60 and older.
-
Intergenerational Interaction Program for Nursing Home Residents and Nursing Students
A 6-week program pairs nursing home residents with nursing students to see if weekly joint activities can increase joy and reduce loneliness for older adults and lessen ageism in students.
-
Supplemental Mobility for older adults in skilled nursing facilities
This pilot tests whether adding a mobility aide to support walking and transfers alongside regular rehab helps older adults in SNFs after hospitalization see more daily activity and safer mobility.
-
Smart Voice Platform to Support Quality of Life for Community-Living Older Adults
A smart voice platform is tested to see if it improves quality of life and healthy aging for older adults living in the community.
-
Digital STEADI: A home-based digital fall prevention program for older adults
A home-based digital program using AI-driven conversational agents tests if a guided fall-prevention exercise plan can reduce fall risk for older adults with mild cognitive impairment living independently.
-
Sex hormones, menopause, and exercise in aging women
This study tests how hormonal status and resistance training affect age-related muscle and nerve function in postmenopausal women.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.